AbbVie has announced that it will be acquiring Aliada Therapeutics for $1.4bn, marking a notable boost to its neuroscience ...

Direct Express is a well-established company based to the north of London – at Welham Green, Hertfordshire – which is close to the M25, M4, M3, M1 and A1(M).

Pharma companion apps are transforming healthcare by offering support beyond traditional treatments, enhancing patient ...

Susanne Bobadilla from VML Health, joined by a team of 15 medical, digital strategists and client engagement experts from across the company, looks at the top trends coming out of ESMO 2024 and what ...

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat resectable non-small cell ...

AstraZeneca’s (AZ) Voydeya (danicopan) has been recommended by the National Institute for Health and Care Excellence (NICE) as an add-on therapy for adults with the rare blood disorder paroxysmal ...

Merck & Co – known as MSD outside the US and Canada – has acquired Yale University oncology spinout Modifi Biosciences in a deal worth $1.3bn. The agreement gives Merck access to preclinical compounds ...

BeiGene’s Tevimbra (tislelizumab) has been recommended by the European Medicines Agency’s human medicines committee as a first-line treatment for gastric and oesophageal cancer patients. The Committee ...

Johnson & Johnson (J&J) has announced that a subcutaneous (SC) formulation of Darzalex (daratumumab) has been approved by the European Commission (EC) as part of a combination treatment for newly ...

Next Wednesday, Rachel Reeves will deliver Labour’s first Budget in 15 years. As anticipation mounts on what will be included – and not included – I’ve taken some time to consider what measures are ...

The health technology assessment agency said that more evidence is needed on the clinical and cost-effectiveness of the drug Eli Lilly’s amyloid plaque-targeting Alzheimer’s disease (AD) drug has been ...